Pharmacological reprogramming of myeloid suppression in solid tumors: mechanisms, evidence standards for immune conversion, and biomarker-informed combinations.
Journal: Frontiers in pharmacology
•
Abstract
Abstract text is not embedded in this discovery record. Please consult the full-text publication via the source link on the right.
Subjects & Keywords
How to Cite this Article
Maletin N, Denda N, Paut Kusturica M, et al. (2026). "Pharmacological reprogramming of myeloid suppression in solid tumors: mechanisms, evidence standards for immune conversion, and biomarker-informed combinations.". Frontiers in pharmacology. https://doi.org/10.3389/fphar.2026.1986842